Screening epidemiological program on compensation evaluation of Diabetes Mellitus type 2 (DMT2) patients on oral anti-diabetic (OAD) monotherapy and physicians satisfaction of their usage

Study identifier:NIS-CRU-ONG-2010/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Screening epidemiological program on compensation evaluation of DM type 2 patients on OAD monotherapy and physicians satisfaction of their usage

Medical condition

Type 2 Diabetes

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1849

Study type

Observational

Age

35 Years +

Date

Study Start Date: 01 Dec 2010
Primary Completion Date: 01 Mar 2011
Study Completion Date: 01 Mar 2011

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Bristol Meyers Squibb

Inclusion and exclusion criteria